via bloomberg.com
AstraZeneca Plc (AZN) won a U.S. court ruling that will help ward off generic competition to the extended-release version of its Seroquel antipsychotic drug until a patent expires in 2017.
U.S. District Judge Joel Pisano in Trenton, New Jersey, ruled today that four generic-drug makers, including Mylan Inc. (MYL), were infringing a patent on the medicine. The judge rejected their arguments that the patent was invalid.
No comments:
Post a Comment